Saag KG, et al. - In this 24-month, double-blind, active-controlled, double-dummy, non-inferiority study, the researchers evaluated the efficacy and safety of denosumab compared with risedronate in glucocorticoid-induced osteoporosis. This investigation was performed at 79 centres in Europe, Latin America, Asia, and North America. In this analysis, eligible patients were aged 18 years or older and were receiving glucocorticoids (≥7·5 mg prednisone daily, or equivalent) for at least 3 months (glucocorticoid continuing) or less than 3 months (glucocorticoid initiating) before screening. For patients newly initiating or continuing glucocorticoids who were at risk of fractures, denosumab could be a useful treatment option.